Dr. Pardo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1855 1st Ave
Ste 200B
San Diego, CA 92101Phone+1 619-793-7988Fax+1 619-269-4302
Education & Training
Harvard Medical SchoolPost-Doctoral Fellowship, 1990 - 1994
Massachusetts General HospitalFellowship, Clinical Oncology, 1990 - 1994- Harvard Medical SchoolPost-Doctoral Fellowship, 1989 - 1990
- Massachusetts General HospitalPost-Doctoral Fellowship, 1989 - 1990
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1986 - 1990- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1986 - 1989
University of California San Francisco School of MedicineClass of 1984
Johns Hopkins UniversityBA/MA, Biophysics, Highest University and Departmental Honors, 1976 - 1980
Certifications & Licensure
CA State Medical License 1986 - 2026
NY State Medical License 1999 - 2024
MA State Medical License 1990 - 2005
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Top Doctor California Magazine, 2021
- The Albert Nelson Marquis Lifetime Achievement Award Marquis Who's Who Publication Board, 2020
Publications & Presentations
PubMed
- 16 citationsImatinib-Mediated Inactivation of Akt Regulates ABCG2 Function in Head and Neck Squamous Cell CarcinomaTheresa S. Chu, Jocelyn S. Chen, Jay Patrick Lopez, Francisco S. Pardo, Joseph A. Aguilera
Archives of Otolaryngology--Head & Neck Surgery. 2008-09-15 - 15 citationsGefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.Jay Patrick Lopez, Jessica Wang-Rodriguez, Catherine Y. Chang, Gabriel Sneh, Michael Andrew Yu
The Laryngoscope. 2008-08-01 - 37 citationsGefitinib Inhibition of Drug Resistance to Doxorubicin by Inactivating ABCG2 in Thyroid Cancer Cell LinesJay Patrick Lopez, Jessica Wang-Rodriguez, Catherine Y. Chang, Jocelyn S. Chen, Francisco S. Pardo
Archives of Otolaryngology--Head & Neck Surgery. 2007-10-01
Grant Support
- Cylcin G1/S Expression And Radiation SensitivityNational Cancer Institute2004
- Cylcin G1/S Expression And Radiation SensitivityNational Cancer Institute2003–2004
- Core--Radiation MedicineNational Cancer Institute2001–2002
- G1/S Regulation And Radiation SensitivityNational Cancer Institute1996–1997
- G1/S Regulation And Radiation SensitivityNational Cancer Institute1995
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
